# Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

> **NCT04098393** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 39 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Busulfan 3.2 mg/kg/day
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Antithymocyte globulin (ATG)
- **DRUG:** Busulfan 0.8 mg/kg
- **PROCEDURE:** Allogeneic hematopoietic cell transplantation (Allo-HCT)

## Key facts

- **NCT ID:** NCT04098393
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-18
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04098393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04098393, "Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04098393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*